Invent Medic Sweden - Q3 financial report
The company’s first product Efemia was launched on the Swedish market on the 1st of OctoberFirst nine months (January – September 2018) · The company’s sales amounted to 0 (0) KSEK. · Other operating income amounted to 17 (153) KSEK. · Capitalised development expenses amounted to 428 (522) KSEK. · Operating costs amounted to 7 048 (5 886) KSEK. · Result before and after tax amounted to -6 604 (-5 211) KSEK. · Result per share amounted to -0,68 (-0,61) SEK. · Cash and cash equivalents at the end of the period amounted to 16 297 KSEK. Third quarter (July –